Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Partidos CD, Stinchcomb DT, Osorio JE.

Vaccine. 2013 Apr 3;31(14):1848-55. doi: 10.1016/j.vaccine.2013.01.038. Epub 2013 Feb 1.

2.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

3.

Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene.

Kamlangdee A, Kingstad-Bakke B, Anderson TK, Goldberg TL, Osorio JE.

J Virol. 2014 Nov;88(22):13300-9. doi: 10.1128/JVI.01532-14. Epub 2014 Sep 10.

4.
5.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

6.

Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice.

Castrucci MR, Facchini M, Di Mario G, Garulli B, Sciaraffia E, Meola M, Fabiani C, De Marco MA, Cordioli P, Siccardi A, Kawaoka Y, Donatelli I.

Influenza Other Respir Viruses. 2014 May;8(3):367-75. doi: 10.1111/irv.12221. Epub 2013 Dec 23.

7.

Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.

Di Mario G, Soprana E, Gubinelli F, Panigada M, Facchini M, Fabiani C, Garulli B, Basileo M, Cassone A, Siccardi A, Donatelli I, Castrucci MR.

Pathog Glob Health. 2017 Mar;111(2):69-75. doi: 10.1080/20477724.2016.1275464. Epub 2017 Jan 12.

PMID:
28081672
8.

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, Schwendinger MG, Pilz A, Barrett PN, Falkner FG, Schäfer B.

PLoS One. 2014 Feb 11;9(2):e88340. doi: 10.1371/journal.pone.0088340. eCollection 2014.

9.

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2009 Feb 1;199(3):405-13. doi: 10.1086/595984.

PMID:
19061423
10.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

11.

Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.

Di Mario G, Sciaraffia E, Facchini M, Gubinelli F, Soprana E, Panigada M, Bernasconi V, Garulli B, Siccardi A, Donatelli I, Castrucci MR.

Pathog Glob Health. 2017 Mar;111(2):76-82. doi: 10.1080/20477724.2016.1275465. Epub 2017 Jan 12.

PMID:
28079473
12.

Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.

Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP.

Vaccine. 2012 May 14;30(23):3413-22. doi: 10.1016/j.vaccine.2012.03.033. Epub 2012 Mar 29.

PMID:
22465746
13.

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG.

J Virol. 2009 May;83(10):5192-203. doi: 10.1128/JVI.02081-08. Epub 2009 Mar 11.

14.

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.

Kreijtz JH, Süzer Y, Bodewes R, Schwantes A, van Amerongen G, Verburgh RJ, de Mutsert G, van den Brand J, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Gen Virol. 2010 Nov;91(Pt 11):2745-52. doi: 10.1099/vir.0.024885-0. Epub 2010 Aug 18.

PMID:
20719991
15.

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

Vaccine. 2009 Oct 23;27(45):6296-9. doi: 10.1016/j.vaccine.2009.03.020.

PMID:
19840663
16.

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG.

PLoS One. 2011 Jan 24;6(1):e16247. doi: 10.1371/journal.pone.0016247.

17.

Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.

Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC, Zhang Q.

Vaccine. 2016 Mar 29;34(14):1688-95. doi: 10.1016/j.vaccine.2016.02.028. Epub 2016 Feb 20.

PMID:
26902548
18.
19.

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2007 Jun 1;195(11):1598-606. Epub 2007 Apr 17.

PMID:
17471429
20.

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

Supplemental Content

Support Center